[go: up one dir, main page]

KR870006027A - 치환 피페라진-1,4-나프탈렌디온과 그 산부가염 및 그들의 제조방법 - Google Patents

치환 피페라진-1,4-나프탈렌디온과 그 산부가염 및 그들의 제조방법 Download PDF

Info

Publication number
KR870006027A
KR870006027A KR860010896A KR860010896A KR870006027A KR 870006027 A KR870006027 A KR 870006027A KR 860010896 A KR860010896 A KR 860010896A KR 860010896 A KR860010896 A KR 860010896A KR 870006027 A KR870006027 A KR 870006027A
Authority
KR
South Korea
Prior art keywords
formula
alkyl
compound
piperazinyl
halogen
Prior art date
Application number
KR860010896A
Other languages
English (en)
Other versions
KR900001189B1 (ko
Inventor
브라이언 메드워드 제프리
웨인 토오리 로오런스
스티븐 톰커후시크 앤드루
Original Assignee
존 제이 헤이간
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 존 제이 헤이간, 아메리칸 사이아나밋드 캄파니 filed Critical 존 제이 헤이간
Publication of KR870006027A publication Critical patent/KR870006027A/ko
Application granted granted Critical
Publication of KR900001189B1 publication Critical patent/KR900001189B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

내용 없음

Description

치환 피페라진-1,4-나프탈렌디온과 그 산부가염 및 그들의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기의 일반식을 화합물들과 약리학적으로 허용되는 2 산부가염.
    여기에서 R1은 할로겐, 히드록시, 알킬(C1-C4), 알콕시(C1-C3), -NHCOCH3혹은 -N(COCH3)2; R2는 수소 혹은 알킬(C1-C4); R3및 R4는 개별적으로 알킬(C1-C3), 또는 함께 결합하여 -(CH2)n- (여기서, n은 2 또는 3의 정수); R5은 수소, 포밀, 아세틸, -COO 알킬(C1-C4), -COOCH2C(할로겐)3, -CO(CH2)7CH=CH(CH2)7CH3, -CON[알킬(C1-C3)]2, 페닐, 벤질, 2-, 3- 또는 4-피리디닐, 2-피리디미닐, 2-,3- 혹은 4-할로벤조일, 2-,3- 혹은 4-알킬-(C1-C6)벤조일. 일치환 페닐(여기서 치환체는 오토, 메타 혹은 파라가 될 것이며, 할로겐 및 트리플루오로메틸로 부터 선택될 것이다),
    일치환 페닐 카르복스아미드(여기서 치환체는 메타 혹은 파라의 위치이고, 할로겐과 트리플루오로메틸로부터 선택될 것이다),
  2. 제1항에 있어서, 화합물이 2-클로로-3-[4-(페닐메틸)-1-피페라지닐]-1, 4-나프탈렌디온, 2-클로로-3-[4-(2-퀴놀리닐)-1-피페라지닐]-1,4-나프탈렌디온, 히드로클로라이드 4-(3-클로로-1,4-디히드로-1,4-디옥소-2-나프탈레닐)-N-[3-(트리플루오로메틸)페닐]-1-피페라진 카르콕스아미드, N-[3-[3-[4-(2-벤조티아존일)-1-피페라지닐]-1,4-디히드로-1,4-디옥소-2-나프탈레닐]아세트 아미드 혹은 2-클로로-3-[4-(2-피리디닐)-1-피페라지닐]-1,4-프탈렌디온, 히드로클로라이드인 화합물.
  3. 제1항에 있어서, 화합물이 2-[[2-(2-벤조티아존일 메틸아미노) 에틸] 메틸아미노]-3-클로로-1,4-타프탈렌디온, 4-(1,4-디히드로-3-메틸-1,4-디옥소-2-나프탈레닐)-1-피페라진-카르복실산, 에틸 에스테르, 2-메틸-3-[4-(페닐 메틸)-1-피페라지닐]-1,4-나프탈렌디온, 2-메틸-3-[4-[3-(트리플루오로메틸)페닐]-1-피페라지닐]-1,4-나프탈렌디온 혹은 2-메틸-3-[4-(2-피리디닐)-1-피페라지닐]-1,4-나프탈렌디온인 화합물.
  4. 하기의 일반식의 화합물로 부터 선택되는 화합물 약 5mg-1500mg으로 구성되는 단위 용량 형태의 조성물,
    여기서 R1,R2,R3,R4및 R5은 제1항에서 정의한 바와 같다.
  5. 2,3-디클로로나프로퀴논을 다음 일반식(2)의 아민과 용매내에서 몇시간 환류시키면서 반응시키는 것으로 구성되는 하기 일반식(1)의 화합물들의 제조 방법.
    여기서 R2,R3,R4및 R5은 제1항에서 정의한 바와 같다.
    여기서 R2,R3,R4및 R5은 제1항에서 정의한 바와 같다.
  6. 2-아세틸아미노-3-클로로-1,4-나프로퀴논을 다음 일반식(4)의 아민과 용매 내에서 반응시키는 것으로 구성되는 하기 일반식(3)의 화합물들의 제조방법.
    여기서 R2,R3,R4및 R5은 제1항에서 정의한 바와 같다.
    여기서 R2,R3,R4및 R5은 제1항에서 정의한 바와 같다.
  7. 하기 일반식(6)의 화합물을 하기 일반식(7)의 페닐이 소시아네이트와 유기용매내에서 반응시키는 것으로 구성되는 하기 일반식(5)의 화합물의 제조 방법.
    여기서 R2은 수소 또는 알킬(C1-C4)이고; R3및 R4는 개별적으로 알킬(C1-C4)이거나, 함께 결합하여 -(CH2)n- (n은 2 또는 3인 정수)가 되고; X는 할로겐이거나 트리플루오로메틸이다.
    여기서 R2, R3및 R4는 전술한 바와 같다.
    여기서 X는 전술한 바와 같다.
  8. 하기 일반식(9)의 화합물과 일반식 ClCOY (10)의 염화 카르보닐을 유기용매내에서 반응시키는 것으로 구성되는 하기 알반식(8)의 화합물의 제조방법.
    여기서 R2는 수소 혹은 알킬(C1-C4);R3및 R4는 개별적으로 알킬(C1-C4)이거나, 혹은 함께 결합하여 -(CH2)n- (여기서 n은 2 또는 3의 정수)이 되고; Y는 0-알킬(C1-C6), 디메틸 아미노, 치환페닐[여기서 치환체는 할로겐 혹은 알킬(C1-C4)가 될 것이다], 0-벤질, -OCH2(할로겐)3또는 -(CH2)7CH=CH(CH)2)7CH3이다
    여기서 R2,R3및 R4는 전술한 바와 같다.
    (10) ClCOY
    여기서 Y는 전술한 바와 같다.
  9. 2,3-에폭시-2-메틸-1,4-나프로퀴논을 다음 일반식(12)의 아민과 유기용매내에서 반응시키는 것으로 구성되는 하기 일반식(11)의 화합물들과 약리학적으로 허용되는 그 산부 가염의 제조방법.
    여기서 R2,R3,R4및 R5은 제1항에서 정의한 바와 같다.
    여기서 R2,R3,R4및 R5는 전술한 바와 같다.
  10. 2,3-에폭시-2,3-디히드로-1,4-나프로퀴논을 다음 일반식(14)의 아민과 유기용매내에서 반응시키는 것으로 구성되는 하기 일반식(13)의 화합물들과 약리학적으로 허용되는 그 산부 가염의 제조방법.
    여기서 R2,R3,R4및 R5은 제1항에서 정의한 바와 같다.
    여기서 R2,R3,R4및 R5는 전술한 바와 같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860010896A 1985-12-19 1986-12-18 치환 피페라진-1,4-나프탈렌디온과 그 산부가염 및 그들의 제조방법. KR900001189B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/811,122 1985-12-19
US06/811,122 US4686220A (en) 1985-12-19 1985-12-19 Substituted 2-[b-substituted-amino)-ethylamino]-1,4-naphthalenediones for treating asthma, allergic diseases and inflammation in warm-blooded animals

Publications (2)

Publication Number Publication Date
KR870006027A true KR870006027A (ko) 1987-07-08
KR900001189B1 KR900001189B1 (ko) 1990-02-27

Family

ID=25205632

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860010896A KR900001189B1 (ko) 1985-12-19 1986-12-18 치환 피페라진-1,4-나프탈렌디온과 그 산부가염 및 그들의 제조방법.

Country Status (13)

Country Link
US (1) US4686220A (ko)
EP (1) EP0226842A3 (ko)
JP (1) JPS62187439A (ko)
KR (1) KR900001189B1 (ko)
AU (1) AU593310B2 (ko)
CA (1) CA1263650A (ko)
DK (1) DK614186A (ko)
FI (1) FI86060C (ko)
HU (1) HU198293B (ko)
IE (1) IE863290L (ko)
NO (1) NO166530C (ko)
NZ (1) NZ218610A (ko)
ZA (1) ZA869525B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882339A (en) * 1987-07-10 1989-11-21 Ciba-Geigy Corporation 4-Amino-substituted 1,2-dihydroxynaphthalene derivatives useful in inhibiting 5-lipoxygenase activity in mammals
US4808586A (en) * 1987-11-23 1989-02-28 American Cyanamid Company Substituted benzimidazoles and benzothidiazoles having anti-asthmatic and/or anti-inflammatory activities
FR2635105B1 (fr) * 1988-08-03 1991-01-25 Synthelabo Derives de piperazine et leur procede de preparation
AU5341699A (en) * 1998-08-06 2000-02-28 University Of Pittsburgh Antiproliferative naphthoquinones, derivatives, compositions, and uses thereof
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2139628A1 (en) * 1971-05-28 1973-01-12 Lipha 5-(4-aryl piperazino-alkyl and alkylene) indans - with tranquillizing activity
JPS5640651A (en) * 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS58177934A (ja) * 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
DE3347657A1 (de) * 1983-12-31 1985-07-11 Troponwerke GmbH & Co KG, 5000 Köln Neue 1,4-naphthochinonderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
HUT44480A (en) 1988-03-28
DK614186D0 (da) 1986-12-18
JPS62187439A (ja) 1987-08-15
IE863290L (en) 1987-06-19
HU198293B (en) 1989-09-28
AU6669186A (en) 1987-06-25
KR900001189B1 (ko) 1990-02-27
DK614186A (da) 1987-06-20
EP0226842A3 (en) 1989-07-19
ZA869525B (en) 1987-08-26
FI865182A0 (fi) 1986-12-18
FI865182A (fi) 1987-06-20
FI86060B (fi) 1992-03-31
NO166530C (no) 1991-08-14
EP0226842A2 (en) 1987-07-01
NO865139L (no) 1987-06-22
FI86060C (fi) 1992-07-10
NO865139D0 (no) 1986-12-18
NZ218610A (en) 1990-04-26
CA1263650A (en) 1989-12-05
AU593310B2 (en) 1990-02-08
US4686220A (en) 1987-08-11
NO166530B (no) 1991-04-29

Similar Documents

Publication Publication Date Title
US4466972A (en) Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
US6090807A (en) Use of heterocyclic compounds
JP4669836B2 (ja) ピペリジニル−およびピペラジニル−アルキルカルバメート誘導体、その製造法および治療用途
RU99122343A (ru) Производные 2-(иминометил)аминофенила, способ их получения, их применение в качестве лекарственных средств и фармацевтические композиции на их основе
RU2001111023A (ru) Новые производные n-(иминометил)аминов, их получение, их использование в качестве лекарственных средств и содержащие их фармацевтические композиции
KR920019756A (ko) 벤조헤테로 고리 화합물
CA2407149A1 (en) Melanin-concentrating hormone antagonist
KR920019784A (ko) 벤조이소티아졸 및 벤조이소옥사졸-3-카복스아미드, 이의 제조방법 및 약제로서의 용도
KR890003742A (ko) 카르바모일키롤리돈 유도체 및 노인성 치매용 약제
US4755512A (en) Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities
KR930702287A (ko) 신규화합물
KR880001616A (ko) P-아미노페놀 유도체
RU2000101328A (ru) Новые 2-(иминометил)аминофенильные производные, способ их получения, их применение в качестве лекарственных средств и содержащие их фармацевтические композиции
KR890008137A (ko) 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
KR910016708A (ko) 엔지오텐신 ii 수용체에 대한 길항성을 갖는 신규한 피라졸 유도체, 이의 제조방법 및 이를 포함하는 제약학적 조성물
US4539322A (en) Dihydropyridine derivatives and their use in treating heart conditions and hypertension
DE3874576D1 (de) 4-(4-(4-(4-((2-(2,4-difluorophenyl)-2-(1h-azolylmethyl)-1,3-dioxolan-4-yl)-methoxy)phenyl)-1-piperazinyl)phenyl)triazolone.
JP2005532331A5 (ko)
KR870006027A (ko) 치환 피페라진-1,4-나프탈렌디온과 그 산부가염 및 그들의 제조방법
JPH0369910B2 (ko)
HU900039D0 (en) Process for preparation of piperidine-derivatives and for manufacturing of the pharmaceutical composition containing these compounds
KR100608416B1 (ko) 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체
EP0194750A1 (en) Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them
KR930702980A (ko) 인단 유도체
KR920000744A (ko) 2-아미노알킬-5-아릴 알킬-1,3- 디옥산 유도체의 제조법 및 치료학적 용도

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19861218

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19870926

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19861218

Comment text: Patent Application

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19900129

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19900528

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19900705

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19900705

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19921223

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 19940113

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 19940113

Start annual number: 5

End annual number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee